Business Context and Reporting Period
This Form 6-K filing is submitted by Mainz Biomed N.V. (noted as Quantum Cyber N.V. in metadata) for the month of November 2025. The registrant is a foreign private issuer headquartered in Mainz, Germany, filing under Rule 13a-16 of the Securities Exchange Act of 1934.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and capital structure amendments rather than financial performance.
Material Changes
On November 13, 2025, the company executed a Deed of Amendment to its Articles of Association with the following primary changes:
- Share Nominal Value: Decreased from €0.40 to €0.01 for both ordinary and preferred shares.
- Authorized Share Capital: Increased to €125,000, divided into 11,250,000 ordinary shares and 1,250,000 preferred shares.
- Future Capital Expansion: If outstanding ordinary shares exceed 10,000,000, authorized capital will increase to €500,000 (45,000,000 ordinary shares and 5,000,000 preferred shares).
- Fractional Shares: Eliminated the ability to issue fractional shares.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or specific risk factors related to operations. The document incorporates the Deed of Amendment by reference into the company's Registration Statement on Form F-3 (File No. 333-269091).
Investor Verification Checklist
- Verify the exact impact of the nominal value reduction on existing shareholder equity and potential dilution.
- Confirm the current number of outstanding ordinary shares to determine if the threshold for the €500,000 capital increase has been met.
- Review the full text of the Deed of Amendment (Exhibit 4.1) for any additional covenants or restrictions not summarized in the filing.
- Check the status of the Form F-3 registration statement to understand how these amendments affect future capital raising capabilities.